Last reviewed · How we verify

NCT03560349

RCT of SPG Blocks for Post-dural Headache

Withdrawn Phase 2 Last updated 13 December 2022
What this trial tests

Phase 2 trial testing Lidocaine HCl Gel 2% in Post-Dural Puncture Headache. Withdrawn.

Timeline
1 July 2018
Primary endpoint
1 January 2019
1 January 2019

Quick facts

Lead sponsorUniversity of Utah
PhasePhase 2
StatusWithdrawn
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposetreatment
Start date1 July 2018
Primary completion1 January 2019
Estimated completion1 January 2019
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

University of Utah

Who can join

Adults 18 to 50, female only, with Post-Dural Puncture Headache. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of the study is to assess the effectiveness of the SPG block with lidocaine vs. SPG block with placebo on preventing the need for EBP in women who develop PDPH after accidental dural puncture during placement of LEA for labor.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Post-Dural Puncture Headache

Currently open trials in the same condition.

Other University of Utah trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03560349.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing